Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Wegovy maker Novo Nordisk and Zepbound manufacturer Eli Lilly directly ... authorization process under the new weight-loss drug benefit. Cigna has made numerous forays into the GLP-1 space.

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...

Evernorth, the pharmacy benefits unit for health insurer ... patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a list price ...

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for ... and two other benefit managers together control 80 percent of the prescription market. The others, Cigna’s Express ...

Cigna's Evernorth is rolling out a new pharmacy ... Scripts arm it negotiated directly with the manufacturers for Wegovy and Zepbound—Novo Nordisk and Eli Lilly, respectively—to cap patients ...